Clinical genitourinary cancer最新文献

{"title":"Regional Lymph Node Dissection is associated with Improved Survival for Patients with Urothelial Cell Carcinoma Undergoing Definitive Surgery","authors":"Abigail Kohut-Jackson,&nbsp;Madison Schanz,&nbsp;Julian Giakas,&nbsp;Paula Buchanan,&nbsp;Krithika Kumanan,&nbsp;Luke Wang,&nbsp;Zachary Hamilton","doi":"10.1016/j.clgc.2025.102456","DOIUrl":"10.1016/j.clgc.2025.102456","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate practice patterns and overall survival outcomes for the performance of radical nephroureterectomy or ureterectomy stratified by utilization of lymph node dissection (LND) for patients with upper tract urothelial cell carcinoma.</div></div><div><h3>Methods</h3><div>The National Cancer Database was queried for patients with upper tract urothelial cell carcinoma, cTanyN0M0 and cTanyN+M0, stratified by LND (pN0-1) versus no lymph node dissection (pNx) from 2006 to 2016. 17,455 patients met criteria for analysis; 9365 patients had primary renal tumors, and 8090 patients had primary ureteral tumors. We retrospectively analyzed trends in overall survival and 30- and 90-day mortality.</div></div><div><h3>Results</h3><div>In the 9365 patients with primary renal or renal pelvis tumors, 48.8% underwent LND with 5.2% having pN+ disease. LND was associated with improved overall survival when compared with no LND (62.3% vs. 57.3%, <em>P</em> &lt; .001). In the 8090 patients with primary ureteral tumors, 50.9% underwent LND and 3.6% had pN+ disease. Similarly, LND was associated with improved overall survival when compared with no LND (61.4% vs. 50.3%, <em>P</em> &lt; .001). Multivariate analysis also demonstrated significant lower overall mortality in ureteral patients undergoing LND controlled for patient and clinical characteristics. Furthermore, in the ureteral group, patients with pN0 disease had improved 5-year-survival compared to pNx disease.</div></div><div><h3>Conclusions</h3><div>LND in the setting of radical nephroureterectomy or ureterectomy has been historically underutilized, with less than half of patients with primary renal or primary ureteral tumors receiving LND from 2006 to 2016. Our analysis demonstrates a potential decreased mortality associated with LND for patients with upper tract urothelial cell carcinoma, notably in those with ureteral tumors, regardless of patient and clinical characteristics.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102456"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urothelial Carcinoma In Situ: Advances in Diagnosis and Management","authors":"Gabriele Ricciardi ,&nbsp;Pietro Tralongo ,&nbsp;Francesco Pierconti ,&nbsp;Valeria Zuccalà ,&nbsp;Vincenzo Fiorentino ,&nbsp;Ludovica Pepe ,&nbsp;Mariagiovanna Ballato ,&nbsp;Antonio Ieni ,&nbsp;Marta Rossanese ,&nbsp;Vincenzo Ficarra ,&nbsp;Guido Fadda ,&nbsp;Maurizio Martini","doi":"10.1016/j.clgc.2025.102478","DOIUrl":"10.1016/j.clgc.2025.102478","url":null,"abstract":"<div><div>Carcinoma in situ (CIS) of the urinary tract is an aggressive, flat, high-grade form of non–muscle-invasive urothelial carcinoma, associated with a high risk of recurrence and progression. Its diagnosis remains challenging due to the absence of specific symptoms and the frequent overlap with benign inflammatory lesions. Although intravesical <em>Bacillus</em> Calmette-Guérin (BCG) remains the standard of care, many patients experience relapse or develop BCG-unresponsive disease, for which effective alternatives are urgently needed. Recent advances in diagnostic techniques, such as narrow band imaging and photodynamic diagnosis, have improved detection accuracy, while novel therapeutic strategies, such as immune checkpoint inhibitors, thermo-chemotherapy, intravescical gene therapy (nadofaragene firadenovec), IL-15 superagonists (eg, ALT-803), and oncolytic viral therapies (eg, CG0070), are expanding the treatment landscape. Furthermore, emerging molecular and immune-related biomarkers may help predict response to therapy and guide personalized management. This review summarizes current evidence on the biology, diagnosis, and treatment of CIS, highlighting key challenges and future directions in the effort to improve patient outcomes and reduce the need for radical cystectomy.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102478"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145806789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Fat and Muscle Mass With Overall Survival in Patients With Metastatic Prostate Cancer Treated With Enzalutamide, Abiraterone, and Docetaxel","authors":"İhsan Solmaz ,&nbsp;Halil Kömek ,&nbsp;Fethullah Kayan ,&nbsp;Canan Can ,&nbsp;İhsan Kaplan ,&nbsp;Rıdvan Kiliç ,&nbsp;Yunus Güzel ,&nbsp;Mehmet Serdar Yildirim ,&nbsp;Ömer Faruk Alakuş ,&nbsp;Bilgin Bahadır Başgöz ,&nbsp;Mehmet Özel ,&nbsp;Eşref Araç","doi":"10.1016/j.clgc.2025.102482","DOIUrl":"10.1016/j.clgc.2025.102482","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the association between fat and muscle mass parameters and overall survival in patients with castration-resistant metastatic prostate cancer (mCRPC) receiving chemotherapy or androgen deprivation therapy.</div></div><div><h3>Materials and Methods</h3><div>This retrospective study included mCRPC patients treated with docetaxel, abiraterone, or enzalutamide between January 01, 2017 and December 31, 2022. CT images at the L3 vertebral level were used to measure the cross-sectional areas of psoas muscle (PM), skeletal muscle (SM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT). These values were normalized by height (cm²/m²) to calculate indices (PMI, SMI, VATI, SATI). Mean hounsfield unit (HU) values of right and left PM were used to assess myosteatosis. Changes in body composition before and after treatment (eg, ΔVATI, ΔSATI) were also calculated. Survival analysis was performed using (ROC) receiver operating curves and Kaplan-Meier tests.</div></div><div><h3>Results</h3><div>Univariate Cox regression showed significant associations between mortality and age, treatment type, right PM HU (pre and post-treatment), left PM HU (post-treatment), post-treatment VATI, ΔSATI, ΔVATI, and baseline PMI (<em>P</em> &lt; .05 for all). In multivariate analysis, post-treatment right PM HU and VATI were independent prognostic factors (<em>P</em> = .02 and <em>P</em> &lt; .001, respectively).</div></div><div><h3>Conclusion</h3><div>Fat mass, sarcopenia, and myosteatosis—especially post-treatment VATI and right PM attenuation—were associated with survival in mCRPC. Fat loss and increased myosteatosis may negatively affect prognosis, highlighting the importance of body composition monitoring during treatment.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102482"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience","authors":"Lennert Eismann ,&nbsp;Stephen W. Reese ,&nbsp;Mark T. Dawidek ,&nbsp;Lina Posada Calderon ,&nbsp;Andreas Aulitzky ,&nbsp;Katiana Vazquez-Rivera ,&nbsp;Jonathan A. Coleman ,&nbsp;Christian G. Stief ,&nbsp;Ed Reznik ,&nbsp;Paul Russo ,&nbsp;Abraham Ari Hakimi","doi":"10.1016/j.clgc.2025.102463","DOIUrl":"10.1016/j.clgc.2025.102463","url":null,"abstract":"<div><h3>Background</h3><div>The natural history of renal oncocytoma (RO) following surgical resection remains unclear. We examined a cohort of post-nephrectomy patients with RO, focusing on the management of synchronous and metachronous tumors and their clinical course under surveillance.</div></div><div><h3>Methods</h3><div>This retrospective, single-institution study analyzed patients from 1990 to 2020 with at least 24 months of follow-up. Patient characteristics and management of synchronous and metachronous tumors were recorded. Cox regression identified risk factors for metachronous tumors, while Kaplan–Meier and log-rank tests assessed metachronous-free survival (MFS).</div></div><div><h3>Results</h3><div>Among 328 patients (median follow-up: 109 months), 19% (<em>n</em> = 63) had synchronous renal tumors on preoperative imaging. Of these, 27 underwent additional procedures, revealing renal cell carcinoma (RCC)/cortical neoplasm (<em>n</em> = 7), benign lesions (<em>n</em> = 5), or secondary RO (<em>n</em> = 13). Two specimens were unavailable. Metachronous renal lesions developed in 8.5% (<em>n</em> = 28), with 18 undergoing active surveillance. Among 8 patients undergoing biopsy or surgery, 3 had RCC/cortical neoplasm, 4 had RO, and 1 specimen was inconclusive. 5-year MFS were 98.8% in patients with a single lesion at diagnosis and 88% for patients with presence of synchronous renal lesions (<em>P</em> = .004). Higher BMI (HR 1.09, CI 1.01-1.17, <em>P</em> = .026) and synchronous lesions at diagnosis (HR 2.67, CI 1.16-6.14, <em>P</em> = .021) were significant risk factors for metachronous tumors.</div></div><div><h3>Conclusion</h3><div>Patients with RO have a very low risk of harboring RCC in synchronous or metachronous lesions, supporting active surveillance as a safe strategy. However, those with synchronous kidney tumors at diagnosis face an increased risk of metachronous disease and may require closer monitoring.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102463"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment Regimen","authors":"Kenrick Ng ,&nbsp;Garima Priyadarshini ,&nbsp;Aaron Prendergast ,&nbsp;Charlotte Ackerman ,&nbsp;Susanna Alexander ,&nbsp;Sarah Rudman ,&nbsp;Han Hsi Wong ,&nbsp;Constantine Alifrangis ,&nbsp;Daniel Lawrence ,&nbsp;Daniel M. Berney ,&nbsp;Ewa Nowosinska ,&nbsp;Jonathan Shamash","doi":"10.1016/j.clgc.2025.102468","DOIUrl":"10.1016/j.clgc.2025.102468","url":null,"abstract":"<div><h3>Background</h3><div>Many patients with relapsed germ cell tumors (GCTs) can still be cured with salvage chemotherapy. Oxaliplatin-based therapies may offer reduced toxicity and noncross resistance to cisplatin-based therapies. PET scan response early during therapy may predict long term outcome.</div></div><div><h3>Methods</h3><div>Eligible patients with GCTs who progressed following cisplatin-based chemotherapy were recruited into this single-arm, phase II clinical trial. Participants received four 21-day cycles of actinomycin D, methotrexate, paclitaxel, and oxaliplatin. The primary endpoint was objective response rate. Secondary endpoints were progression-free survival (PFS), overall survival and toxicity. A survival analysis was performed based on International Prognostic Factors Study Group (IPFSG) classes. The early predictive value of response on PET CT after 1 cycle of treatment was also assessed.</div></div><div><h3>Results</h3><div>Forty four patients received at least 1 dose of the study medication between 2012 and 2020. The median age was 38, and 70% had intermediate, high or very high-risk disease by IPFSG criteria. The objective response rate of the evaluable population was 59.0%. The median combined radiological or tumor marker PFS was 9.7 months (95% CI, 3.0-22.0 months). At a median follow-up of 26.9 months, the median overall survival was not reached (95% CI, 17.8-NR). Analyses of outcomes based on IPFSG showed relatively favorable outcomes in patients with high and very high-risk disease, with a 2-year combined PFS rates of 33%. PET CT response after 1 cycle of treatment did not predict PFS benefit.</div></div><div><h3>Conclusions</h3><div>The GAMMA regimen demonstrates encouraging antitumor activity in relapsed GCT, despite recruiting a cohort of patients with predominantly poor risk disease.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102468"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with Immunotherapy","authors":"Abby L. Grier ,&nbsp;Albert Jang ,&nbsp;Jeffrey Y. Zhong ,&nbsp;Hamsa L.S. Kumar ,&nbsp;Tanya Jindal ,&nbsp;Adam Calaway ,&nbsp;Angela Y. Jia ,&nbsp;Pingfu Fu ,&nbsp;Laura Bukavina ,&nbsp;Rashed Ghandour ,&nbsp;Jonathan E. Shoag ,&nbsp;Randy Vince ,&nbsp;Santosh Rao ,&nbsp;Iris Sheng ,&nbsp;Prateek Mendiratta ,&nbsp;Jason R. Brown ,&nbsp;Shilpa Gupta ,&nbsp;Jorge A. Garcia ,&nbsp;Pedro C. Barata","doi":"10.1016/j.clgc.2025.102483","DOIUrl":"10.1016/j.clgc.2025.102483","url":null,"abstract":"<div><h3>Introduction</h3><div>Immune checkpoint inhibitors are a standard of care in managing locally advanced and metastatic genitourinary cancers.</div></div><div><h3>Methods</h3><div>We evaluated the utilization of immune checkpoint inhibitors as subsequent therapy in patients enrolled to 11 registrational phase III cancer immunotherapy trials that demonstrated an overall survival benefit.</div></div><div><h3>Results</h3><div>For renal cell carcinoma (<em>n</em> = 5135 patients, 2014-2019), approximately 60% of control-arm patients received subsequent therapy upon progression, with 70% of those receiving an immune checkpoint inhibitor. For urothelial carcinoma (<em>n</em> = 3445 patients, 2015-2022), 54% of control-arm patients received subsequent therapy upon progression, with 69% of those receiving an immune checkpoint inhibitor.</div></div><div><h3>Conclusion</h3><div>Patients randomized to the control arm of these trials did not consistently receive immune checkpoint inhibitors upon progression. Further research is needed to understand how access to subsequent therapies impacts overall survival, and to identify factors associated with inconsistent provision of subsequent therapies.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102483"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145967993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates","authors":"Wadih Issa ,&nbsp;Maureen Aliru ,&nbsp;Song Zhang ,&nbsp;Damla Gunenc ,&nbsp;Changchuan Jiang ,&nbsp;Qian Qin ,&nbsp;Suzanne Cole ,&nbsp;Waddah Arafat ,&nbsp;Jue Wang ,&nbsp;Daniel Yang ,&nbsp;Neil Desai ,&nbsp;Aurelie Garant ,&nbsp;Raquibul Hannan ,&nbsp;Orhan K. Oz ,&nbsp;Solomon Woldu ,&nbsp;Yair Lotan ,&nbsp;Claus Roehrborn ,&nbsp;Kevin Courtney ,&nbsp;Andrew Z. Wang ,&nbsp;Tian Zhang","doi":"10.1016/j.clgc.2025.102476","DOIUrl":"10.1016/j.clgc.2025.102476","url":null,"abstract":"<div><h3>Background</h3><div>Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is highly sensitive, enabling detection of disease not visualized on conventional imaging, and leading to a new disease state: PSMA-avid/CT-negative metastatic prostate cancer. The optimal management and treatment outcomes for this group remain poorly defined. We investigated whether treatment intensification with androgen receptor signaling inhibitors (ARSI) provides additional benefit for these patients.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of patients with metastatic hormone-sensitive prostate cancer (mHSPC) diagnosed via standard-of-care PSMA PET/CT imaging (Ga68 gozetotide/PSMA-11) at our institution. Patients were stratified based on whether PSMA-avid lesions (SUVmax &gt; 2.5) had correlates on conventional imaging: PSMA (+)/CT (−) versus PSMA (+)/CT (+). We compared prostate-specific antigen progression-free survival (PSA PFS) and castration resistance-free survival (CRFS) between cohorts. OS was not assessed.</div></div><div><h3>Results</h3><div>Among 159 patients, 81 (51%) had PSMA (+)/CT (−) and 78 (49%) had PSMA (+)/CT (+) disease. With a median follow up of 23 months, patients with PSMA (+)/CT (−) mHSPC had significantly longer PSA PFS (hazard ratio [HR] 0.31, <em>P</em> = .01) and CRFS (HR 0.08, <em>P</em> &lt; .001). Within the PSMA (+)/CT (−) cohort, ARSI intensification did not improve CRFS compared to androgen deprivation therapy (ADT) monotherapy (HR 0.32, <em>P</em> = .33).</div></div><div><h3>Conclusions</h3><div>Patients with PSMA (+)/CT (−) mHSPC exhibit a more favorable prognosis with reduced risk of PSA progression and castration resistance compared to those with PSMA (+)/CT (+) disease. However, among patients treated with ADT alone, CRFS was similar across groups, suggesting that the benefit of ARSI intensification in PSMA (+)/CT (−) patients requires prospective validation.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102476"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Treatment and Survival in Locally Advanced Prostate Cancer: Real-World Outcomes","authors":"Anne Holck Storås ,&nbsp;Kaitlyn M Tsuruda ,&nbsp;Tor Åge Myklebust ,&nbsp;Erik S Haug ,&nbsp;Sophie D Fosså ,&nbsp;Bettina Kulle Andreassen","doi":"10.1016/j.clgc.2025.102480","DOIUrl":"10.1016/j.clgc.2025.102480","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate real-world postoperative treatment patterns and survival outcomes among men with nonmetastatic locally advanced prostate cancer (laPCa) undergoing radical prostatectomy (RP) to improve the shared decision-making process.</div></div><div><h3>Material and Methods</h3><div>All 3022 patients diagnosed with laPCa prostate cancer and registered in Cancer registry of Norway (CRN) who underwent RP within 1 year after diagnosis during 2008-21 were included. Data on disease characteristic’s and radiotherapy were derived from the CRN and data on endocrine treatment and additional systemic therapy (docetaxel, abiraterone, enzalutamide) were provided from the Norwegian Prescription Database and the Norwegian Patient Registry. Cause-specific mortality was estimated using a competing risk framework. Overall survival was calculated as 1 minus the all-cause mortality. The cumulative probability of starting postoperative treatment for relapse was also calculated.</div></div><div><h3>Results</h3><div>Median follow-up was 4.8 years. Within 10 years post-RP, 34% received postoperative radiotherapy, 19% received endocrine therapy as first treatment, and 14% received additional systemic therapy. Higher PSA, cT3b stage, and ISUP grade 4 to 5 were associated with increased likelihood of postoperative treatment. The 10-year overall mortality was 16%, with most deaths from non-prostate cancer causes. Patients receiving postoperative radiotherapy had low 10-year prostate cancer-specific mortality (2%), whereas those starting endocrine therapy first experienced higher prostate cancer mortality (31%). Among patients progressing to systemic therapy, 5-year mortality was 65%, predominantly due to prostate cancer.</div></div><div><h3>Conclusion</h3><div>In this large, unselected national cohort, laPCa patients treated with RP had generally favorable long-term survival, but more than half required relapse-directed therapy within 10 years. Relapse risk was strongly linked to baseline tumor characteristics and persisted throughout follow-up, underscoring the need for prolonged surveillance. Future studies should address long-term functional outcomes and quality-of-life after multimodal postoperative treatment.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102480"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Survival and Recurrence After Partial or Radical Nephrectomy in Women with Localized Renal Cell Carcinoma: A Multicenter Analysis","authors":"Mai R. Dabbas ,&nbsp;Melis Guer ,&nbsp;Giacomo Musso ,&nbsp;Giuseppe Garofano ,&nbsp;Margaret F. Meagher ,&nbsp;Dhruv Puri ,&nbsp;Kit L. Yuen ,&nbsp;Umberto Capitanio ,&nbsp;Alessandro Larcher ,&nbsp;Cesare Saitta ,&nbsp;Breanna Kim ,&nbsp;Sanjana Karamcheti ,&nbsp;Benjamin H. Baker ,&nbsp;Kazutaka Saito ,&nbsp;Yosuke Yasuda ,&nbsp;Dattatraya Patil ,&nbsp;Alberto Briganti ,&nbsp;Andrea Salonia ,&nbsp;Yasuhisa Fujii ,&nbsp;Viraj Master ,&nbsp;Ithaar H. Derweesh","doi":"10.1016/j.clgc.2025.102460","DOIUrl":"10.1016/j.clgc.2025.102460","url":null,"abstract":"<div><h3>Introduction</h3><div>Renal cell carcinoma (RCC) is marked by significant gender differences in incidence. While RCC is more common in men, limited data exist on survival outcomes in women following surgery. We investigated survival outcomes and predictive factors in women with localized RCC.</div></div><div><h3>Patients and Methods</h3><div>We conducted a retrospective multicenter analysis of women who underwent surgery for Stage I–III RCC. Primary outcome was recurrence. Multivariable Cox regression assessed predictors of All-Cause Mortality (ACM), Cancer-Specific Mortality (CSM), and recurrence. Kaplan–Meier analysis (KMA) evaluated overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) across racial/ethnic groups.</div></div><div><h3>Results</h3><div>We analyzed 3218 women (median age 61 years; follow-up 63 months), with 454 (14.1%) experiencing recurrence. On multivariable analysis, high Charlson score (HR 1.89, <em>P</em> &lt; .001), AJCC stage II/III (HR 2.44, <em>P</em> &lt; .001), high-grade (HR 2.24, <em>P</em> &lt; .001), and positive margins (HR 2.02, <em>P</em> &lt; .001) were associated with recurrence. Black race (HR 0.68, <em>P</em> = .046) and chromophobe histology (HR 0.32, <em>P</em> = .002) were protective. For ACM, increasing age (HR 1.04, <em>P</em> &lt; .001), High/Intermediate Charlson score (HR 1.52, HR 1.34: <em>P</em> = .006, <em>P</em> &lt; .001), AJCC stage II/III (HR 1.46, <em>P</em> &lt; .001), high-grade (HR 1.51, <em>P</em> &lt; .001), GFR &lt;45 (HR 1.63, <em>P</em> &lt; .001), recurrence (HR 1.45, <em>P</em> &lt; .001) were predictive, while Asian (HR 0.40, <em>P</em> &lt; .001) and Hispanic (HR 0.53, <em>P</em> = .048) race were protective. CSM was associated with age (HR 1.04, <em>P</em> &lt; .001), AJCC stage II/III (HR 2.06, <em>P</em> = .006), high-grade (HR 1.62, <em>P</em> &lt; .001), and recurrence (HR 5.38, <em>P</em> &lt; .001); Asian race (HR 0.52, <em>P</em> &lt; .001) was protective. KMA showed significant differences in OS and CSS (<em>P</em> &lt; .001), but not RFS (<em>P</em> = .136).</div></div><div><h3>Conclusion</h3><div>In addition to known clinico-pathologic predictors, ethno-racial differences were noted in survival and recurrence among women with RCC. Recurrence was a major determinant of mortality. Black women had lower recurrence risk, while Asian and Hispanic women had improved survival. These findings highlight the influence of systemic disparities beyond tumor biology.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102460"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145598253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Oncologic Outcomes of Cryoablation, Laser Ablation, and Hyperthermia for Localized Prostate Cancer: A Population-Based Cohort Study Using the SEER Database","authors":"Run-Qi Guo,&nbsp;Jie Sun,&nbsp;Zhi-Xin Bie,&nbsp;Yuan-Ming Li","doi":"10.1016/j.clgc.2025.102490","DOIUrl":"10.1016/j.clgc.2025.102490","url":null,"abstract":"<div><h3>Objective</h3><div>Ablative therapies, including cryoablation (CA), laser ablation (LA), and hyperthermia (HT), are increasingly used for localized prostate cancer, but large-scale comparative evidence on their long-term oncologic outcomes is scarce. This study aimed to compare cancer-specific survival (CSS) and overall survival (OS) among patients treated with these modalities.</div></div><div><h3>Methods</h3><div>Using the Surveillance, Epidemiology, and End Results (SEER) database (2000-2019), we identified patients with localized prostate cancer treated with CA, LA, or HT between 2010 and 2019. Propensity score matching (PSM) at a 1:1 ratio was performed to balance baseline characteristics. OS and CSS were estimated using the Kaplan–Meier method, and competing risk analysis was performed to assess cancer-specific mortality (CSM) and other-cause mortality (OCM).</div></div><div><h3>Results</h3><div>After PSM, 712 patients per group were compared between CA and LA. No significant difference was observed in CSS (Hazard Ratio [HR] = 1.58, 95% Confidence Interval [CI] 0.94-2.66; <em>P</em> = .083) or OS (HR = 1.09, 95% CI, 0.88-1.35; <em>P</em> = .481). The median follow-up was 64 months, with 18 and 23 cancer-specific deaths in the CA and LA groups, respectively. In comparisons involving HT (<em>n</em> = 107 per group post-PSM), no statistically significant differences in survival were detected against CA or LA. However, these HT-related findings must be interpreted with extreme caution due to the significant heterogeneity of the HT category, the small sample size, and resulting low statistical power.</div></div><div><h3>Conclusion</h3><div>In this large population-based study, CA and LA demonstrated comparable long-term oncologic outcomes for localized prostate cancer. While no survival differences were detected for HT, definitive conclusions cannot be drawn for this modality due to major methodological limitations. Further prospective, well-designed randomized controlled trials are essential to validate these findings and provide more robust evidence.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"24 1","pages":"Article 102490"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}